Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03903705 | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 348 | HutchmedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT02454010 | A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer | completed | Phase 1 | 73 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT04236414 | Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours | completed | Phase 1 | 16 | AstraZenecaINDUSTRY | 6 | Apr 4, 2025 | clinicaltrials |
| NCT01877382 | A Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 107 | Daiichi SankyoINDUSTRY | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05584111 | Oral Administration of STC-15 in Subjects With Advanced Malignancies | completed | Phase 1 | 42 | STORM Therapeutics LTDINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT01543763 | Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors | completed | Phase 1 | 90 | Pamela MunsterOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05463432 | A Study of HR19024 in Subjects With Advanced Solid Tumor | completed | Phase 1 | 71 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | completed | Phase 1 | 56 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | completed | Phase 1 / Phase 2 | 89 | Agenus Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06873542 | A Study of DC05F01 in Chinese Patients with Advanced or Metastatic Solid Tumors | completed | Phase 1 | 10 | Heronova PharmaceuticalsINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04882917 | First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410) | completed | Phase 1 | 22 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 2 | Mar 7, 2025 | clinicaltrials |
| NCT03444701 | A Study of E7130 in Participants With Solid Tumors | completed | Phase 1 | 62 | Eisai Co., Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT03761017 | MGD019 DART® Protein in Unresectable/Metastatic Cancer | completed | Phase 1 | 162 | MacroGenicsINDUSTRY | 5 | Mar 6, 2025 | clinicaltrials |
| NCT04105335 | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)(TIMEPOINT) | completed | Phase 1 | 50 | Mina Alpha LimitedINDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT01585623 | Drug Interaction Study of SAR302503 in Patients With Solid Tumor | completed | Phase 1 | 16 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04608045 | Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors | completed | Phase 1 | 9 | CicloMed LLCINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01251562 | Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors | completed | Phase 1 | 50 | BPGbioINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT01957735 | BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors | completed | Phase 1 | 97 | BPGbioINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT03956680 | An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers | completed | Phase 1 | 54 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT05188664 | Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 20 | LaNova Australia Pty LimitedINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03654716 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05943041 | Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer | completed | Phase 1 | 9 | GILongevityINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT02070549 | Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Feb 13, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04805307 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 | completed | Phase 1 | 176 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06172894 | PBMC-based Leukocyte Immunotherapy(PALINDROM) | completed | Phase 1 | 10 | invIOs GmbHINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT02188264 | Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer | completed | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 2 | Feb 11, 2025 | clinicaltrials |
| NCT05178888 | Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | completed | Phase 1 | 11 | Mirati Therapeutics Inc.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT02503709 | Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2025 | clinicaltrials |
| NCT02631733 | Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 10, 2025 | clinicaltrials |
| NCT02667873 | A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors | completed | Phase 1 | 72 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT02876510 | ACTolog in Patients With Solid Cancers(ACTolog) | completed | Phase 1 | 38 | Immatics US, Inc.INDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT03247309 | TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)(ACTengine) | completed | Phase 1 | 7 | Immatics US, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03441100 | TCR-engineered T Cells in Solid Tumors: IMA202-101(ACTengine) | completed | Phase 1 | 16 | Immatics US, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT03628677 | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | completed | Phase 1 | 75 | Arcus Biosciences, Inc.INDUSTRY | 2 | Feb 4, 2025 | clinicaltrials |
| NCT04574583 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2025 | clinicaltrials |
| NCT03447470 | Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | completed | Phase 1 | 46 | Redx Pharma LtdINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT06258330 | Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors | completed | Phase 1 | 12 | Aummune Ltd.INDUSTRY | 1 | Jan 28, 2025 | clinicaltrials |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | completed | Phase 1 | 52 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT01946789 | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | completed | Phase 1 | 26 | Altor BioScienceINDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT02240238 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | completed | Phase 1 / Phase 2 | 119 | NanoCarrier Co., Ltd.INDUSTRY | 5 | Jan 22, 2025 | clinicaltrials |
| NCT05613036 | A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body | completed | Phase 1 | 13 | Boehringer IngelheimINDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT03518606 | Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours(MOVIE) | completed | Phase 1 / Phase 2 | 126 | UNICANCEROTHER | 1 | Jan 15, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2025source: clinicaltrials